The abstract is read at the publisher; the summary is JClub's.
Positive phase 3 trials for nerandomilast and inhaled treprostinil are changing the treatment landscape for idiopathic pulmonary fibrosis (IPF), which previously relied on two antifibrotic drugs.
- Why it matters: The field needs updated options beyond the long-standing antifibrotic strategy, as multiple emerging therapies are now in clinical development for IPF.
- What they did: This Trial Watch reviews five emerging approaches, highlighting new therapies in mid- and late-stage development that target fibrosis through different mechanisms.
- The result: The review points clinicians to five emerging directions to watch, suggesting a rapidly evolving pipeline beyond the two established antifibrotic drugs for IPF.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.